Immunotherapy and Hepatocellular Carcinoma

Ingham, Matthew; Wu, Jennifer

doi:10.4172/2167-0889.1000e108

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Programmed death-1 (PD-1) is expressed in immune cells and programmed death ligand 1 (PD-L1) could be expressed in cancer cells [4]. Inhibitory signals are generated by the binding of PD-1 and PD-L1 in T cells to inhibit immune response and T cell activation [5]. Cytotoxic T lymphocyte protein 4 (CTLA-4) is also expressed in the T cells and other immune cells, and the blockade of it could activate immune response [6].…”

Section: Introductionmentioning

confidence: 99%

Research Progress in Target Cancer of Immune Checkpoint Inhibitors

Wang¹

2023

HSET

View full text Add to dashboard Cite

Despite the long-standing emphasis on the role of T lymphocytes in cancer immunosurveillance, initiatives to improve the effectiveness of antitumor immune responses have been stimulated by the recognition that tumors may evade the response of T cells. Current research progress in T-cell immunobiology contributed to overcoming tumor immune escape mechanisms. Because of the inhibition of T-cell regulatory type in cancer patients, immune checkpoint inhibitors have shown significant antitumor activity. In this paper, we systematically review the current research progress on immune checkpoint inhibitors in tumor therapy in recent years to improve the accuracy of immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Research Progress in Target Cancer of Immune Checkpoint Inhibitors

Wang¹

2023

HSET

View full text Add to dashboard Cite

show abstract

Immunotherapy and Hepatocellular Carcinoma

Cited by 1 publication

References 33 publications

Research Progress in Target Cancer of Immune Checkpoint Inhibitors

Research Progress in Target Cancer of Immune Checkpoint Inhibitors

Contact Info

Product

Resources

About